Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Promising results for nivolumab in advanced liver cancer

2015 ASCO Annual Meeting

29 May - 2 Jun 2015

Published: 29 May 2015

Views: 2807

Rating:

Save

Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA

Dr Anthony El-Khoueiry presents at a press conference at ASCO 2015 findings from a phase I/II study that suggest nivolumab is safe and effective in advanced liver cancer.

Read the news article or watch the interview for more.

Related Videos

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable...

Dr Riccardo Lencioni - University of Pisa, Pisa, Italy

Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma ( Dr Riccardo Lencioni - University of Pisa, Pisa, Italy )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses...

Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types ( Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA )

More from ecancer